

New Products - Nesina

Nesina (**alogliptin benzoate**) is an orally bioavailable reversible inhibitor of the enzymatic activity of dipeptidyl peptidase-4 (DPP-4), an enzyme that rapidly degrades incretin hormones. DPP 4 inhibition increases circulating blood levels of endogenous incretins. Nesina is indicated to improve glycaemic control in adult patients (≥ 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control, as add on to metformin, a sulphonylurea, a thiazolidinedione, insulin (with or without metformin), or in combination with metformin and a thiazolidinedione when dual therapy does not provide adequate glycaemic control. Nesina is available as a 6.25 mg, 12.5 mg and 25 mg film coated tablet in packs of 28's.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.